17:00 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other molecule...
19:05 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria Mouse studies suggest an RNA-based vaccine encoding Plasmodium MIF could help prevent malaria infection. The vaccine consists of a lipid nanoparticle (LNP) loaded with Plasmodium MIF encoded by an alphaviral RNA replicon. In mouse...
22:06 , Jun 14, 2018 |  BC Innovations  |  Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
22:41 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal damage Patient sample, cell culture and mouse studies suggest MIF or its receptor CD74 could help treat ischemia/reperfusion-associated acute kidney injury (AKI). In serum samples from 60 cardiac bypass surgery patients who experienced surgery-related...
18:48 , May 4, 2018 |  BC Week In Review  |  Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from 51 amyotrophic lateral sclerosis (ALS) patients without non-invasive ventilation in a Phase Ib/IIa trial showing that once-daily 60 mg oral ibudilast (Ketas, AV411, MN-166) plus riluzole non-significantly...
18:47 , May 4, 2018 |  BC Week In Review  |  Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from the Phase IIb SPRINT-MS trial in 255 patients with primary or secondary progressive multiple sclerosis showing that twice-daily oral ibudilast (Ketas, AV411, MN-166) met the secondary endpoint...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...
15:16 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported on March 29 that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat methamphetamine dependence. The trial enrolled about 140...
18:59 , Mar 29, 2018 |  BC Extra  |  Clinical News

MediciNova sinks after meth dependence failure

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) lost $1.74 (15%) to $10.22 on NASDAQ Thursday after reporting that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat...